News
Products
MSDS
PEGylation

PEGylation is the process of modification of biological molecules by covalent conjugation with polyethylene glycol (PEG). PEGylation is being used as a universal therapeutic technique to provide diverse conjugation with peptides, proteins,  antibody fragments, aptamers, enzymes, and small molecules, and has expanded clinical applications for biopharma industries. Dozens of PEGylated drugs are currently on the market for the treatment of cancer, chronic kidney diseases, hepatitis, multiple sclerosis, hemophilia, and gastrointestinal disorders, etc. 

PEGylation improves the pharmacokinetics of the molecule (by reducing clearance and increasing half-life), increases the dosing interval, and improves patient convenience compared to non-PEGylated products. In addition, PEGylation of therapeutic agents is medically valuable in reducing immunogenicity, antigenicity, and toxicity, as well as significantly reducing the renal clearance of the drug while maintaining drug efficacy.

Biopharma PEG provides thousands of PEG linkers (PEGylation reagents) - maleimide,  pyridyl disulfide, amine, carboxylic acids and NHS esters functionalized PEG, such as nh2-peg-nh2mPEG-NH2, which can be linked with proteins, typical reactive amino acids include lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, serine, threonine, tyrosine. Also, Biochempeg provides custom PEG synthesis services to meet our customer's different PEGylation needs.

References:
1. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315-29. doi: 10.2165/00063030-200822050-00004. PMID: 18778113.
2. Ramos de la Peña, Ana Mayela & Aguilar, Oscar. (2020). Progress and Challenges in PEGylated Proteins Downstream Processing: A Review of the Last 8 Years. International Journal of Peptide Research and Therapeutics. 26. 10.1007/s10989-019-09840-4. 
3. Poovi, Ganesan and Narayanasamy Damodharan. “Pegylation : Concept , Application , Characterization , PEG Reagents and its Various Shapes and Functionalization Agent.” (2018).

Catalog No. Name Structure M.W. Purity
MD002002 OH-PEG8-OH OH-PEG8-OH 370.436 ≥95%
MD001003 mPEG5-SH mPEG5-SH 268.4 ≥95%
MD001003 mPEG6-SH mPEG6-SH 312.42 ≥95%
MD005005 NH2-PEG8-NH2 NH2-PEG8-NH2 412.5 ≥95%
MD005005 NH2-PEG12-NH2 NH2-PEG12-NH2 588 ≥95%
MD068121 Boc-NH-PEG2-CH2COOH Boc-NH-PEG2-CH2COOH 263.3 ≥95%
MD068121 Boc-NH-PEG3-CH2COOH Boc-NH-PEG3-CH2COOH 307.34 ≥95%
MF001005 mPEG-NH2 mPEG-NH2 ≥95%
MF001006 mPEG-N3 mPEG-N3 ≥95%
MF001212 mPEG-pALD mPEG-pALD ≥95%
MF001335 mPEG-bALD mPEG-bALD ≥95%
MF001098 mPEG-DPPE mPEG-DPPE ≥95%